UnknownPhase 2NCT05330624
Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens
Studying Plague
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
- Principal Investigator
- Fengcai Zhu, MasterJiangsu Provincial Center for Diseases Control and Prevention
- Intervention
- plague vaccine(F1+rV)(biological)
- Enrollment
- 720 target
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05330624 on ClinicalTrials.govOther trials for Plague
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07207408Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of AgeDynavax Technologies Corporation
- RECRUITINGPHASE1NCT06943378Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy AdultsJust-Evotec Biologics
- RECRUITINGNANCT06083649The Dental Care Revolution: Health Education Using AI or Humanized Counseling on Plague Control and Periodontal Treatment Outcome in Patients With Periodontal DiseaseKaohsiung Medical University Chung-Ho Memorial Hospital